This content is in French.
The STRIDE protocol in hepatocellular carcinoma
27 février 2024
Here, researchers present 4-year overall survival data from the HIMALAYA phase III clinical trial, evaluating the efficacy and safety of STRIDE (Single Tremelimumab Regular Interval Durvalumab) versus sorafenib in…
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
B Sangro et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol. 2024 Feb 19:S0923-7534(24)00049-8.
View the source
